Study May Suggest New Strategies for Myelodysplastic Syndromes Treatment

MD Anderson News Release 05/11/2015

A study revealing fresh insight about chromosome “tails” called telomeres may provide scientists with a new way to look at developing treatments or even preventing a group of blood cell disorders known as myelodysplastic syndromes (MDS).

Researchers at The University of Texas MD Anderson Cancer Center have discovered a direct link between telomere degeneration and MDS. Telomeres, found at the tail ends of chromosomes, are sometimes described as similar to plastic shoelace tips because they prevent chromosome ends from fraying, causing genetic havoc.

Degrading telomeres can sometimes lead to MDS, also thought to be associated with age, gender (more common in men), smoking, previous cancer treatment with radiation or chemotherapy, and family history. MDS is one of the more common blood disorders in the elderly with 90 percent of cases affecting people over age 60.

“MDS risk correlates with advancing age, therapy-induced DNA damage, and/or shorter telomeres, but whether telomere erosion directly causes MDS is unknown,” said Simona Colla, Ph.D., assistant professor of Leukemia. “Our study provided genetic evidence that DNA damage caused by telomere loss is linked to this disorder.”

Findings by Colla, fellow first co-author Derrick Ong, Ph.D., Odyssey fellow of Genomic Medicine, and corresponding author Ron DePinho, M.D., professor of Cancer Biology and  MD Anderson president, are published in the May 11, 2015 issue of Cancer Cell.

The team’s mouse and human cell study found that DNA damage caused by dysfunctional telomeres resulted in repressed expression of a gene called SRSF2. SRSF2 is a RNA splicing gene that plays a role in cellular processes. This change impacted blood cells named CMPs (common myeloid progenitors), affecting their ability to differentiate or fully mature.

“This study established an intimate link across telomere biology, aberrant RNA splicing and CMP differentiation,” said DiPinho. “This may suggest that strategies to mitigate this DNA damage may be useful for preventing and/or treating MDS.”

Colla added that their findings “were consistent with long-standing observations that poor prognosis in MDS correlates strongly with short telomeres and elevated DNA damage in CMP cells.”

“This improved understanding should provide highly specific risk biomarkers for preventing and treating this incurable disease,” said Colla.

The study was funded by the National Cancer Institute (RO1 CA084628, CA 143883), the Laura and John Arnold Foundation and the National Institutes of Health (P30 CA16672).

MD Anderson team members included Yamini Ogoti, Matteo Marchesini, Ph.D., Irene Ganan Gomez, Ph.D., Marcos Estecio, Ph.D., Yu Wei, Ph.D., Hui Yang, Ph.D., Marianna D’Anca, Hagop Kantarjian, M.D., and Guillermo Garcia-Manero, M.D., all of Leukemia; Paola Storti, Ph.D., Andrea Viale, M.D., Ph.D., David Weksberg, M.D., Ph.D., Yan Wing Ho, Baoli Hu, Ph.D., Giannicola Genovese, Ph.D.,  Piergiorgio Pettazzoni, Ph.D., Shan Jiang, Sujun Hua, Ph.D., Alessandro Carugo, Luigi Nezi, Ph.D., Alan Wang,Ph.D., and Lynda Chin, M.D., Genomic Medicine; Nipun Mistry, Li Zhang, Ph.D., and Han Liang, Ph.D., Bioinformatics and Computational Biology; Karen Clise-Dwyer, Ph.D., and Kathryn Ruisaard, Stem Cell Transplantation and Cellular Therapy; Sonny Ang, Ph.D., and Laurence Cooper, M.D., Pediatrics; Christopher Bristow, Ph.D., James Horner, Philip Jones, Ph.D., and Timothy Heffernan, Ph.D., Institute for Applied Cancer Science; Sarah Gaddis and Tim Gong, Ph.D., Molecular Carcinogenesis; Asha Multani, Ph.D., Genetics; and Carlos Bueso-Ramos, Ph.D. Hematopathology.

Other participating institutions included the University of Parma, Parma, Italy, and In Silico Solutions, Falls Church, Va.